Fateeha Furqan, MD

Peer-Reviewed Articles

1. Shah, N, Colina, AS, Johnson, BD, Szabo, A, Furqan, F, Kearl, TJ, Schneider, D, Vargas-Cortes, M, Schmeling, JL, Dwinell, MB, Palen, K, Longo, W, Hematti, P, Zamora, AE, Hari, PN, Bucklan, D, Cunningham, A, Hamadani, M, Fenske, TS. Phase I/II Study of Adaptive Manufactured Lentiviral Anti-CD20/Anti-CD19 Chimeric Antigen Receptor T Cells for Relapsed, Refractory Mantle Cell Lymphoma. Journal of Clinical Oncology 43(20):2285-2295, 2025. e-Pub 2025. PMID: 40163793.
2. Furqan F, Ahn KW, Kaur M, Patel J, Ansell S, Awan FT, Baird J, Bezerra E, Farooq U, Fung H, Khurana A, Lekakis L, Lutfi F, McCarty J, Mukherjee A, Nath R, Romancik J, Schuster SJ, Smith M, Winter A, Turtle C, Sauter C, Shadman M, Herrara A, Hamadani M. Autologous Transplant or CAR-T as Consolidation Options in MYC Rearranged Large B-Cell Lymphoma Patients in Remission After Salvage Treatments. American journal of hematology 100(7):1152-1162, 2025. e-Pub 2025. PMID: 40231369.
3. Zelikson, V, Gurumurthi, A, Sawalha, Y, Annunzio, K, Saha, A, Dong, N, Qualls, D, Amoozgar, B, Kahl, BS, Baird, JH, Challa, P, Huntington, SF, Santos, J, Bair, SM, Narkhede, M, Li, S, Frosch, Z, Ho, C, Smith, SD, Winter, AM, Landsburg, DJ, Furqan, F, Hamadani, M, Baird, K, Romancik, JT, Alharthy, H, Law, JY, Bojanini, L, Advani, RH, Hu, B, Johnson, PC, Grover, N, Merril, M, Crombie, JL, Shafagati, N, Sterling, C, Nastoupil, L, Epperla, N, Ayers, EC. Loncastuximab in high-risk and heavily pretreated relapsed/refractory diffuse large B-cell lymphoma. Haematologica 110(3):706-714, 2025. e-Pub 2025. PMID: 39540227.
4. Wesson, W, Dima, D, Suleman, N, Saif, MI, Tabak, C, Logan, E, Davis, JA, McGann, M, Furqan, F, Mohan, M, Rashid, A, Abdallah, AO, Ullah, F, Shune, L, Mushtaq, MU, Raza, S, McGuirk, J, Hamadani, M, Anwer, F, Hashmi, H, Ahmed, N. Timing of Toxicities and Non-Relapse Mortality Following CAR T Therapy in Myeloma. Transplantation and Cellular Therapy 30(9):876-884, 2024. e-Pub 2024. PMID: 38871056.
5. Furqan, F, Bhatlapenumarthi, V, Dhakal, B, Fenske, TS, Farrukh, F, Longo, W, Akhtar, O, D'Souza, A, Pasquini, MC, Guru Murthy, GS, Runaas, L, Abedin, S, Mohan, M, Shah, N, Hamadani, M. Outpatient administration of CAR T-cell therapies using a strategy of no remote monitoring and early CRS intervention. Blood Advances 8(16):4320-4329, 2024. e-Pub 2024. PMID: 38889435.
6. Furqan, F, Shah, N. The Role of Noncovalent BTK Inhibitors in the Era of Covalent BTK Inhibitors. Clinical Advances in Hematology and Oncology 22(3):140-147, 2024. e-Pub 2024. PMID: 38588273.
7. Arshad, S, Fang, X, Ahn, KW, Kaur, M, Scordo, M, Sauter, C, Furqan, F, Awan, FT, Hamadani, M. Impact of thiotepa dose-intensity in primary diffuse large B-cell lymphoma of the central nervous system undergoing autologous hematopoietic cell transplant with thiotepa/carmustine conditioning. Bone marrow transplantation 58(11):1203-1208, 2023. e-Pub 2023. PMID: 37563283.
8. Bowers, JT, Anna, J, Bair, SM, Annunzio, K, Epperla, N, Pullukkara, JJ, Gaballa, S, Spinner, MA, Li, S, Messmer, M, Nguyen, J, Ayers, EC, Wagner, C, Hu, B, Di, M, Huntington, SF, Furqan, F, Shah, N, Chen, C, Ballard, HJ, Hughes, ME, Chong, EA, Nasta, S, Barta, S, Landsburg, DJ, Svoboda, J. Brentuximab vedotin plus AVD for Hodgkin lymphoma. Blood Advances 7(21):6630-6638, 2023. e-Pub 2023. PMID: 37595053.
9. Furqan F, Xu H, Zurko J, Fenske TS, Johnson B, Hamadani M, Shah NN. Single Cell Cytokine Analyses of Bispecific, Tandem, Anti-CD20, Anti-CD19 CAR T-Cells from Patients with Relapsed, Refractory B-Cell Malignancies 140(1):12690-12691, 2022. e-Pub 2022.
10. Shah NN, Furqan F, Szabo A, Neumann J, Longo WL, Hari P, Schneider D, Johnson B, Fenske TS, Hamadani M. 8-Day Versus 12-Day Manufactured LV20. 19 CAR T-Cells for B-Cell Non-Hodgkin Lymphoma. Blood 140(Supplement 1):7480–7481, 2022.
11. Strati P, Ahmed S, Furqan F, Fayad LE, Lee HJ, Swaminathan P, Iyer, Nair R. Prognostic impact of corticosteroids on efficacy of chimeric antigen receptor T-cell therapy in large B-cell lymphoma. Blood, The Journal of the American Society of Hematology 137(23):3272-3276, 2021. PMID: 33534891.
12. Marques-Piubelli, Mario L, Schlette EJ, Khoury JD, Furqan F, Vega F, Solis Soto LM, et al IIW. Expression of BCL2 alternative proteins and association with outcome in CLL patients treated with venetoclax, 2020. e-Pub 2020. PMID: 33327833.
13. Furqan F, Sham R, Kouides P. Efficacy and Safety of Half-Dose Desmopressin for Bleeding Prophylaxis in Bleeding Disorder Patients undergoing predominantly low to moderate risk invasive procedures, 2020. e-Pub 2020. PMID: 32628278.
14. Tariq, Raseen, Saha S, Furqan F, Hassett L, Pardi D, Khanna S. Prevalence and mortality of COVID-19 patients with gastrointestinal symptoms: a systematic review and meta-analysis. In Mayo Clinic Proceedings 95(8):1632-1648, 2020. PMID: 32753138.
15. Tbakhi, Bushra, Furqan F, Scott G, Liesveld JL, S Aljitawi AO. Autologous stem cell rescue recipient with neutrophil tissue delivery detected prior to blood engraftment: A case report 1(1):330-33, 2020. e-Pub 2020. PMID: 32924026.
16. Tariq R, Furqan F, Pardi D, Khanna S. Efficacy of Fecal Microbiota Transplantation for Acute Graft Versus Host Disease in the Gut: A Systematic Review and Meta-Analysis: 201. American Journal of Gastroenterology, 2019.
17. Tariq R, Furqan F, Jamshed S, Khanna S. Risk Factors of Clostridium Difficile Infection in Hematopoietic Stem Cell Transplant Recipients: A Systemic Review and Meta-Analysis. Blood 132(1):4704-4704, 2018. e-Pub 2018.
18. Tariq R, Saha S, Wahab A, Furqan F, Olson E, Pardi D, Khanna S. Efficacy of Fecal Microbiota Transplantation for Clostridium difficile Infection in Immunocompromised Patients: A Systematic Review and Meta-Analysis: 207. ACG, 2018.
19. Tariq R, Furqan F, Wahab A, Saha S, Silver S, Khanna S. Association of Proton Pump Inhibitors with Spontaneous Bacterial Peritonitis in Patients with Cirrhosis: An Adjusted Meta-Analysis of Observational Studies: 1015. American Journal of Gastroenterology:570-S572, 2018. e-Pub 2018.

Review Articles

1. Kearl, TJ, Furqan, F, Shah, N. CAR T-cell therapy for B-cell lymphomas. Cancer and Metastasis Reviews 44(1), 2025. e-Pub 2025. PMID: 39617795.
2. Ahmed, G, Furqan, F, Nasrollahi, E, Hamadani, M. Bispecific antibodies in the treatment of relapsed/refractory large B-cell lymphoma. Expert review of anticancer therapy 24(8):705-715, 2024. e-Pub 2024. PMID: 38809821.
3. Furqan F, Shah NN. Multispecific CAR T Cells Deprive Lymphomas of Escape via Antigen Loss. Annual Review of Medicine 74:279-291, 2023. e-Pub 2023. PMID: 36332638.
4. Furqan F, Shah NN. Bispecific CAR T-cells for B-cell malignancies. Expert Opinion on Biological Therapy 22(8):1005-1015, 2022. e-Pub 2022. PMID: 35653589.
5. Furqan F, Hamadani M. Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma: a review of clinical data. Therapeutic Advances in Hematology 13, 2022. e-Pub 2022. PMID: 35340719.

Other Articles

1. Furqan F, Strati P Miscellaneous Complications of Chimeric Antigen Receptor T-Cell Therapy. In: Bashir Q, Shpall EJ, Champlin RE, eds. Manual of Hematopoietic Cell Transplantation and Cellular Therapies. Elsevier:537-547, 2024.
2. Furqan F, Fenske TS, Longo WL, Johnson B, Hamadani M, Shah NN MRD Status By Clonoseq® Is a Poor Predictor of Long- Term Outcomes after Bispecific LV20. 19 CAR T-Cell Therapy for Relapsed, Refractory B-Cell NHL. Blood 140(Supplement 1):6407-6408, 2022.
3. Furqan F, Ahn KW, Chen Y, Kaur M, Abutalib SA, Ahmed N, Ahmed S Allogeneic haematopoietic cell transplant in patients with relapsed/refractory anaplastic large cell lymphoma. British journal of hematology:54-63, 2022. PMID: 36120837.
4. Shah, Nirav N, Furqan F Results from a Phase 1/2 Study of Tandem, Bispecific Anti-CD20/Anti-CD19 (LV20. 19) CAR T-Cells for Mantle Cell Lymphoma 140(Supplement 1 (2022)):9318-9319, 2002.

Editorials

1. Furqan, F, Strati, P. Could a TCR be faster than a CAR?. Blood 147(10):1008-1010, 2026. PMID: 41785007.

Abstracts

1. Lee SS, Mohamed YI, Lee SH, Baird A, Dolan J, Furqan F, Omar Kaseb A. Risk score and prognostication modeling based on mRNA expressivity in the tumor microenvironment of hepatocellular carcinoma. ASCO.
2. Tariq R, Furqan F, Jamshed S, Khanna S. Risk Factors of Clostridium Difficile Infection in Hematopoietic Stem Cell Transplant Recipients: A Systemic Review and Meta-Analysis. ASH.
3. Furqan F, Goldstein N, Kouides PA. Congenital FVIII/IX or VWF Deficiency Does Confer a Lower Rate of Myocardial Infarction-Related Mortality Despite Decreased Cardiovascular Interventions. ASH.
4. Furqan F, Tariq R, Goldstein N, Kashinath S, Jamshed S, Khanna S. Trends in the incidence and outcomes of Clostridioides difficile infection in hematological cancers: A nationwide analysis. ASCO.
5. Tariq R, Furqan F, Pardi D, Khanna S. Efficacy of Fecal Microbiota Transplantation for Acute Graft Versus Host Disease in the Gut: A Systematic Review and Meta-Analysis: 201. ACG.
6. Hassan H, Rafae A, Iftikhar N, Furqan F, Iftikhar A, Mushtaq A, et al AA. Role of extra corporeal methods for light chain removal on renal recovery in multiple myeloma: A systematic review. ASH.
7. Tariq R, Furqan F, Jamshed S, Khanna S. Efficacy of Fecal Microbiota Transplant in Hematological Cancers Patients with Recurrent Clostridioides Difficile Infection: A Systemic Review and Meta-Analysis. ASH.
8. Ahmed S, Furqan F, Strati P, Westin J, Fayad L, Hagemeister FB, Lee HJ. Haemophagocytic lymphohistiocytosis (HLH) in patients with large B-cell lymphoma treated with standard of care (SOC) axicabtagene ciloleucel (Axi-cel). ASCO.
9. Furqan F, Schlette EJ, Vega F, Wistuba II. Alessandra Expression of BCL2 Alternative Proteins and Association with Outcomes in CLLPatients Treated with Venetoclax. AACR.
10. Lee SS, Mohamed YI, Lee SH, Baird A, Dolan J, Furqan F, Omar Kaseb A. Risk score and prognostication modeling based on mRNA expressivity in the tumor microenvironment of hepatocellular carcinoma. ASCO.
11. Hayat MH, Gross S, Enslin S, Furqan F, Tariq R, Kaul V. Trends in the Age-Adjusted Incidence Rates, Prevalence and Survival for Pancreatic Cancer: Results from National Database. ACG.
12. Furqan F, Schlette EJ, Vega F, Wistuba II. Alessandra Expression of BCL2 Alternative Proteins and Association with Outcomes in CLLPatients Treated with Venetoclax. AACR.
13. Strati P, Furqan F, Westin J, Fayad L, Ahmed S, Lee HJ, Padmanabhan S. Prognostic impact of dose, duration, and timing of corticosteroid therapy in patients with large B-cell lymphoma treated with standard of care axicabtagene ciloleucel (Axi-cel). ASCO.
14. Furqan F, Tariq R, Zafar A, Khaild N, Said B, Manogna D, Jadhav N. Low Rates of Hepatocellular Cancer. Screening in a Resident Run Clinic: A Retrospective Review. New York Chapter American College of Physicians.
15. Furqan F, Aschenbrenner E, Talano J, Moskop A, Longo W, Bryon D, Johnson, Fenske TS, Hamadani M, Shah NN. Clinical Characteristics and Patient Outcomes with HLH-like Toxicities after CD19 Based CAR T-Cell Therapy. Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR. Tandem Meetings.
16. Furqan F, Johnson BD, Hamadani M, Fenske TS, N Shah N. Bispecific Anti-CD20/Anti-CD19 (LV20. 19) CAR T-Cells for Richter’s Transformation. Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR.

Letters to the Editor

1. Chohan, KL, Saul, EE, Davis, RE, Hagemeister, FB, Steiner, RE, Fayad, LE, Ahmed, S, Rodriguez, A, Iyer, SP, Nair, R, Vega Vazquez, F, Chihara, D, Strati, P, Jain, P, Malpica Castillo, LE, Nze, CC, Furqan, F, Chauhan, A, Hamilton, MP, Henderson, J, Lionel, A, Flowers, CR, Neelapu, SS, Green, M, Westin, JR. Long-term clinical outcomes from the smart start trial. Blood cancer journal 16, 2026.
2. Furqan F, Maring M, Szabo A, Fenske TS, Hamadani M, Shah NN. Salvage polatuzumab and allogeneic transplant rescue patients with B-cell lymphoma failing CAR T-cell therapy. Blood Advances 7: 2463-2467, 2023.